We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Perspective

Value-based healthcare: implications for thyroid cancer

    Anita K Ying

    *Author for correspondence:

    E-mail Address: akying@mdanderson.org

    University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

    Search for more papers by this author

    ,
    Thomas W Feeley

    University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

    Harvard Business School, Boston, MA 02163, USA

    Search for more papers by this author

    &
    Michael E Porter

    Harvard Business School, Boston, MA 02163, USA

    Search for more papers by this author

    Published Online:8 Apr 2016https://doi.org/10.2217/ije-2015-0005

    Abstract

    Today's delivery of care to thyroid cancer patients is complex, and costly, with uneven outcomes that can be improved. The incidence of thyroid cancer is rising and requires coordinated, multidisciplinary care with high volume centers that is not always available in our current fragmented healthcare system. To address the needs of patients, providers and payers, we believe that thyroid cancer care needs to be reexamined from the perspective of value for the patient, which is defined as the outcomes that matter to patients relative to the cost of delivering them. This paper provides recommendations based on the key principles of the value-based approach to transform the delivery of thyroid cancer care.

    Papers of special note have been highlighted as: • of interest; •• of considerable interest

    References

    • 1 Porter ME, Teisberg ED. Redefining Healthcare: Creating Value-Based Competition on Results. Harvard Business School Press, Boston, MA, USA (2006). •• The definitive textbook that began the value-based healthcare movement in the USA.Google Scholar
    • 2 Porter ME, Lee TH. The strategy that will fix healthcare. Hav. Bus. Rev. 91(10), 50–70 (2013). • A concise review of the six essential aspects of creating a value-based healthcare program.Google Scholar
    • 3 Porter ME. What is value in healthcare? N. Engl. J. Med. 363(26), 2477–2481 (2010).Google Scholar
    • 4 Kaplan RS, Porter ME. How to solve the cost crisis in healthcare. Hav. Bus. Rev. 89(9), 47–64 (2011). •• Reviews a new approach to controlling spiraling healthcare costs – accurate measurement.Google Scholar
    • 5 French KE, Albright HW, Frenzel JC et al. Measuring the value of process improvement initiatives in a preoperative assessment center using time-driven activity-based costing. Healthcare 1(3–4), 136–142 (2013). • Describes how accurate costing can be used to shape and assess performance improvement.Google Scholar
    • 6 Porter ME, Clifford MM, Landman ZC. Orthochoice: bundled payments in the county of Stockholm (a). Harvard Business School Supplement. (Case 714–514), (2015).Google Scholar
    • 7 SEER stat fact sheets: Thyroid cancer (2015). www.seer.cancer.gov/statfacts/html/thyro.html.Google Scholar
    • 8 Sherman SI. Thyroid carcinoma. Lancet 361(9356), 501–511 (2003).Google Scholar
    • 9 Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol. Head Neck Surg. 140(4), 317–322 (2014).Google Scholar
    • 10 Aschebrook-Kilfoy B, Schechter RB, Shih YC et al. The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epideomiol Biomakers Prev. 22(7), 1252–1259 (2013).Google Scholar
    • 11 Ramsey S, Blough D, Kirchhoff A et al. Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health affairs. 32(6), 1143–1152 (2013).Google Scholar
    • 12 Haugen BR, Alexander EK, Bible KC et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1–133 (2015). • The most updated US guidelines on the management of differentiated thyroid cancer.Google Scholar
    • 13 Tuttle RM, Haddad RI, Ball DW et al. Thyroid carcinoma, version 2.2014. J. Natl Compr. Canc. Netw. 12(12), 1671–1680; quiz 1680 (2014).Google Scholar
    • 14 Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167–1214 (2009).Google Scholar
    • 15 Roman BR, Feingold JH, Patel SG et al. The 2009 American Thyroid Association guidelines modestly reduced radioactive iodine use for thyroid cancers less than 1 cm. Thyroid 24(10), 1549–1550 (2014).Google Scholar
    • 16 AJCC Cancer Staging Manual (7th Edition). Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds). Springer, NY, USA (2010).Google Scholar
    • 17 Francis G, Waguespack SG, Bauer AJ et al. American Thyroid Association Guidelines Task Force. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid 25(7), 716–759 (2015). • First published US guidelines on the management of differentiated thyroid cancer in the pediatric population.Google Scholar
    • 18 Rivkees SA, Mazzaferri EL, Verburg FA et al. The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy. Endocr Rev. 32(6), 798–826 (2011).Google Scholar
    • 19 Aschebrook-Kilfoy B, Ward MH, Sabra MM et al. Thyroid cancer incidence patterns in the United States by histologic type,1992–2006. Thyroid 21(2), 125–134 (2011).Google Scholar
    • 20 Wells SA Jr, Asa SL, Dralle H et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6), 567–610 (2015). • The most updated US guidelines on the management of medullary thyroid cancer.Google Scholar
    • 21 Vigersky RA, Fish L, Hogan P et al. The clinical endocrinology workforce: Current status and future projections of supply and demand. J. Clin. Endocrinol. Metab. 99(9), 3112–3121 (2014).Google Scholar
    • 22 Schneider DF, Ojomo KA, Chen H et al. Remnant uptake as a postoperative oncologic quality indicator. Thyroid 23(10), 1269–1276 (2013).Google Scholar
    • 23 Loyo M, Tufano RP, Gourin CG. National trends in thyroid surgery and the effect of volume on short-term outcomes. Laryngoscope 123(8), 2056–2063 (2013).Google Scholar
    • 24 Stavrakis AI, Ituarte PH, Ko CY et al. Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery. Surgery 142(6), 887–899 (2007).Google Scholar
    • 25 Youngwirth LM, Adam MA, Scheri RP et al. Patients treated at low-volume centers have higher rates of incomplete resection and compromised outcomes: analysis of 31,129 patients with papillary thyroid cancer. Ann. Surg. Onco. 23(2), 403–409 (2015).Google Scholar
    • 26 Haymart MR, Banerjee M, Yang D et al. Variation in the management of thyroid cancer. J. Clin. Endocrinol. Metab. 98(5), 2001–2008 (2013).Google Scholar
    • 27 Haymart MR, Banerjee M, Yang D et al. The relationship between extent of thyroid cancer surgery and use of radioactive iodine. Ann. Surg. Oncol. 258(2), 354–358 (2013).Google Scholar
    • 28 Schuessler KM, Banerjee M, Yang D et al. Surgeon training and use of radioactive iodine in stage i thyroid cancer patients. Ann. Surg. Oncol. 20(3), 733–738 (2013).Google Scholar
    • 29 Haymart MR, Banerjee M, Yang D et al. The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer. Cancer 119(2), 259–265 (2013).Google Scholar
    • 30 Wang TS, Roman SA, Sosa JA. Predictors of outcomes following pediatric thyroid and parathyroid surgery. Curr. Opin Oncol. 21(1), 23–28 (2009).Google Scholar
    • 31 Sacks W, Wong RM, Bresee C et al. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer. Thyroid 25(4), 377–385 (2015).Google Scholar
    • 32 Gning I, Trask PC, Mendoza TR et al. Development and initial validation of the thyroid cancer module of the M.D. Anderson symptom inventory. Oncology 76(1), 59–68 (2009).Google Scholar
    • 33 Dadu R, Hu MI, Cleeland CS et al. The efficacy of the natural clay, casad, in reducing medullary thyroid cancer-related diarrhea and its effects on quality of life: a pilot study. Thyroid 24(S1), P166 (2014).Google Scholar
    • 34 Steele JR, Clarke RK, Terrell JA et al. Improving patient access to an interventional us clinic. Radiographics 34(1), e18–e23 (2014).Google Scholar
    • 35 Tuttle RM, Tala H, Shah J et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new american thyroid association staging system. Thyroid 20(12), 1341–1349 (2010).Google Scholar
    • 36 Lindsey SC, Ganly I, Palmer F et al. Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. Thyroid 25(2), 242–249 (2015).Google Scholar